FIND A BIOALPS ACTOR
blur-business-close-up-287227

Oculis raises CHF20 million and moves to Switzerland

03.05.2018
Share this article
Oculis, a clinical-stage biotechnology company focused on the development of non-invasive topical treatment for back-of-the-eye diseases, announced it has successfully closed a Series B financing round of CHF 20 million. In conjunction with the financing, Oculis is re-locating its corporate headquarters to Lausanne.